SRPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-10), Sarepta Therapeutics's current share price is $123.35. Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $10.34. Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is 11.93.
The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PB Ratio was 38.73. The lowest was 3.66. And the median was 11.59.
SRPT's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Sarepta Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $10.172. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.34 for the trailing ten years ended in Mar. 2024.
The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 14.02 | 11.40 | 11.98 | 9.55 | 12.52 |
For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 123.35 | / | 10.34 | |
= | 11.93 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Sarepta Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 10.172 | / | 131.7762 | * | 131.7762 | |
= | 10.172 |
Current CPI (Mar. 2024) = 131.7762.
Sarepta Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 7.351 | 100.560 | 9.633 |
201409 | 6.929 | 100.428 | 9.092 |
201412 | 5.995 | 99.070 | 7.974 |
201503 | 4.855 | 99.621 | 6.422 |
201506 | 3.983 | 100.684 | 5.213 |
201509 | 2.937 | 100.392 | 3.855 |
201512 | 4.172 | 99.792 | 5.509 |
201603 | 3.036 | 100.470 | 3.982 |
201606 | 2.537 | 101.688 | 3.288 |
201609 | 7.518 | 101.861 | 9.726 |
201612 | 6.149 | 101.863 | 7.955 |
201703 | 7.811 | 102.862 | 10.007 |
201706 | 6.826 | 103.349 | 8.704 |
201709 | 10.797 | 104.136 | 13.663 |
201712 | 12.181 | 104.011 | 15.433 |
201803 | 11.860 | 105.290 | 14.844 |
201806 | 10.536 | 106.317 | 13.059 |
201809 | 9.594 | 106.507 | 11.870 |
201812 | 14.524 | 105.998 | 18.056 |
201903 | 18.191 | 107.251 | 22.351 |
201906 | 14.788 | 108.070 | 18.032 |
201909 | 13.358 | 108.329 | 16.249 |
201912 | 10.882 | 108.420 | 13.226 |
202003 | 14.685 | 108.902 | 17.770 |
202006 | 13.296 | 108.767 | 16.109 |
202009 | 11.322 | 109.815 | 13.586 |
202012 | 9.597 | 109.897 | 11.508 |
202103 | 6.714 | 111.754 | 7.917 |
202106 | 6.077 | 114.631 | 6.986 |
202109 | 5.872 | 115.734 | 6.686 |
202112 | 10.651 | 117.630 | 11.932 |
202203 | 9.793 | 121.301 | 10.639 |
202206 | 8.299 | 125.017 | 8.748 |
202209 | 4.909 | 125.227 | 5.166 |
202212 | 4.377 | 125.222 | 4.606 |
202303 | 7.652 | 127.348 | 7.918 |
202306 | 7.949 | 128.729 | 8.137 |
202309 | 8.172 | 129.860 | 8.293 |
202312 | 9.168 | 129.419 | 9.335 |
202403 | 10.172 | 131.776 | 10.172 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Barry | director | 285 MARGALITA DRIVE, SAN RAFAEL CA 94901 |
Douglas S Ingram | director, officer: President & CEO | 2525 DUPONT DR, IRVINE CA 92612 |
Michael Andrew Chambers | director | 215 FIRST STREET, CAMBRIDGE MA 02142 |
Wigzell Hans Lennart Rudolf | director | OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935 |
Bilal Arif | officer: Chief Tech Ops Officer | 215 FIRST STREET, CAMBRIDGE MA 02129 |
Stephen Mayo | director | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Kathryn Jean Boor | director | 3736 S. MAIN STREET, MARION NY 14505 |
Louise Rodino-klapac | officer: Chief Scientific Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
M Kathleen Behrens | director | 6701 KAISER DRIVE, FREMONT CA 94555 |
Ryan Edward Brown | officer: SVP, General Counsel | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
Ian Michael Estepan | officer: Chief Financial Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
Joseph Bratica | officer: Principal Financial Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
David T Howton | officer: SVP, General Counsel | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
John C Martin | director | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Sandesh Mahatme | officer: Senior Vice President, CFO | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
From GuruFocus
By Business Wire • 10-25-2023
By Business Wire • 09-29-2023
By Business Wire • 01-16-2024
By sperokesalga sperokesalga • 04-14-2023
By Business Wire • 06-30-2023
By Business Wire • 07-05-2023
By Business Wire • 01-08-2024
By Business Wire • 08-31-2023
By Business Wire • 12-30-2023
By sperokesalga sperokesalga • 04-15-2023